# Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

> **NCT00324155** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 681 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Placebo
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT00324155
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2011-01
- **Final completion:** 2013-10
- **Target enrollment:** 681 (ACTUAL)
- **Last updated:** 2014-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00324155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00324155, "Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00324155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*